DOCSLIB.ORG

Ctbp Represses Adult Β-Like Globin Expression in Haematopoiesis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Ctbp Represses Adult Β-Like Globin Expression in Haematopoiesis CtBP represses adult -like globin expression in haematopoiesis Jinfen Jasmine Yik A thesis submitted for the degree of Doctor of Philosophy (Biotechnology) School of Biotechnology and Biomolecular Sciences University of New South Wales October 2017 ORIGINALITY STATEMENT i Table of Contents Table of Contents ORIGINALITY STATEMENT ......................................................................................................... i Acknowledgements ................................................................................................................... v Publications arising from this candidature ................................................................................ vi Abstract .................................................................................................................................. vii List of abbreviations ............................................................................................................... viii 1 Chapter 1: Introduction .................................................................................................... 1 1.1 Mammalian gene regulation ..................................................................................... 1 1.2 Gene regulatory elements......................................................................................... 1 1.3 Transcription factors ................................................................................................. 2 1.4 Haematopoiesis ........................................................................................................ 2 1.5 Erythropoiesis ........................................................................................................... 3 1.6 Haemoglobin ............................................................................................................ 4 1.7 The - and -like globin loci ...................................................................................... 4 1.7.1 The α-like globin locus ....................................................................................... 5 1.7.2 The -like globin locus ....................................................................................... 6 1.8 Haemoglobin switching ............................................................................................. 6 1.9 Haemoglobinopathies ............................................................................................... 8 1.9.1 -Haemoglobinopathy ...................................................................................... 8 1.9.2 -Haemoglobinopathy ...................................................................................... 8 1.10 Understanding haemoglobin switching ..................................................................... 9 1.11 Current therapeutic approaches to haemoglobinopathies ........................................ 9 1.12 Transcriptional regulation of erythropoiesis .............................................................10 1.12.1 GATA1 ..............................................................................................................10 1.12.2 FOG1 ................................................................................................................11 1.12.3 Kruppel-Like Factors .........................................................................................11 1.12.4 SOX6 ................................................................................................................13 1.12.5 C-terminal binding proteins ..............................................................................14 1.13 Filling the gap in the knowledge: CtBP .....................................................................15 1.14 Gene editing: CRISPR/Cas9 .......................................................................................16 1.15 Hypothesis & Aims ...................................................................................................17 2 CHAPTER 2: Material and Methods ..................................................................................19 2.1 Materials .................................................................................................................19 2.1.1 Chemicals and Reagents ...................................................................................19 2.1.2 Enzymes ...........................................................................................................22 2.1.3 Antibodies ........................................................................................................22 2.1.4 Cytokines .........................................................................................................22 2.1.5 Plasmids ...........................................................................................................23 2.1.6 Oligonucleotides (Primers and ssODN) .............................................................23 iii 2.1.7 Bacterial strains and culture .............................................................................27 2.1.8 Commercial services and kits............................................................................27 2.2 Methods ..................................................................................................................27 2.2.1 General methods .............................................................................................27 2.2.2 Mammalian cell culture and Nucleofection ......................................................28 2.2.3 Genome editing: CRISPR/Cas9 ..........................................................................29 2.2.4 RNA extraction and cDNA synthesis..................................................................31 2.2.5 Quantitative real-time RT-PCR and Microarrays ...............................................31 2.2.6 Fluorescence-activated cell sorting and flow cytometry ...................................32 2.2.7 Microarray .......................................................................................................32 2.2.8 Statistical analysis ............................................................................................32 3 Chapter 3: The role of CtBP1, CtBP2 and SOX6 on -like globin regulation in HUDEP-2 cells 34 3.1 Introduction.............................................................................................................34 3.1.1 The human erythroid progenitor cell line: HUDEP-2 .........................................34 3.1.2 Existing knowledge on the roles of CtBP and SOX6 in -like globin regulation ...35 3.2 Determining endogenous expression of CtBP1, CtBP2 and SOX6 in HUDEP-2 ...........36 3.3 CRISPR/Cas9 gene engineering and validation of CtBP1-/-, CtBP2-/- and Sox6-/- HUDEP-2 clones ..................................................................................................................37 3.3.1 Western blot screening and validation of CtBP1-/- HUDEP-2 clones .................39 3.3.2 Western blot screening and validation of CtBP2-/- HUDEP-2 clones .................40 3.3.3 Western blot screening and validation of Sox6-/- HUDEP-2 clones....................41 3.4 Knocking out CtBP1 and CtBP2 in HUDEP-2 cells ......................................................43 3.5 Evaluation of -like globin expression in CtBP1-/-, CtBP2-/-, and Sox6-/- HUDEP-2 clones 43 3.6 CtBP1 ablation leads to downregulation of -globin expression in HUDEP-2 cells .....44 3.7 CtBP2 ablation leads to the down-regulation of -globin expression in HUDEP-2 cells 45 3.8 SOX6 ablation has no effect on -globin gene expression in HUDEP-2 cells ..............46 3.9 Discussion ................................................................................................................47 4 Chapter 4: CtBP represses adult - globin regulation in immature murine erythroid cells 51 4.1 Introduction.............................................................................................................51 4.1.1 Choosing MEL cells for the generation of mutant clones ..................................51 4.1.2 Evaluating the roles of CtBP1 and CtBP2 in -like globin expression in MEL cells 52 4.2 Generation and validation of CtBP1-/-, CtBP2-/-, CtBP1CtBP2-/-, Klf3-/-, Klf8-/-, Klf3Klf8-/-, and Sox6-/- mutations in CRISPR/Cas9 modified MEL cells .................................53 4.2.1 Screening and validation of CtBP1-/-, CtBP2-/-, and CtBP1CtBP2-/- MEL clones 55 4.2.2 Screening and validation of Klf3-/-, Klf8-/-, and Klf3Klf8-/- MEL clones .............61 4.2.3 Screening and validation of Sox6-/- MEL clones ................................................67 Table of Contents 4.3 Generation and validation of Sox6ΔDL and Klf3ΔDL mutations in MEL cells ..............69 4.3.1 Screening and validation of Sox6ΔDL MEL clones..............................................71 4.3.2 Screening and validation of Klf3ΔDL MEL clones ...............................................73 4.4 -like globin expression levels in CtBP1-/-, CtBP2-/-, CtBP1CtBP2-/-, Klf3-/-, Klf8-/-, Klf3Klf8-/-, Sox6-/-, Klf3∆DL, and Sox6∆DL MEL clones.........................................................75 4.4.1 -like globin expression levels in undifferentiated and induced differentiated CtBP1-/-, CtBP2-/- and CtBP1CtBP2-/- MEL clones ...........................................................76 4.4.2 Evaluating-like globin expression levels in undifferentiated and induced differentiated Klf3-/-, Klf3∆DL, Klf8-/-, and Klf3Klf8-/- MEL clones ...................................79 4.4.3 -like
Load more

Recommended publications
  • Table 2. Functional Classification of Genes Differentially Regulated After HOXB4 Inactivation in HSC/Hpcs
    Table 2. Functional classification of genes differentially regulated after HOXB4 inactivation in HSC/HPCs Symbol Gene description Fold-change (mean ± SD) Signal transduction Adam8 A disintegrin and metalloprotease domain 8 1.91 ± 0.51 Arl4 ADP-ribosylation factor-like 4 - 1.80 ± 0.40 Dusp6 Dual specificity phosphatase 6 (Mkp3) - 2.30 ± 0.46 Ksr1 Kinase suppressor of ras 1 1.92 ± 0.42 Lyst Lysosomal trafficking regulator 1.89 ± 0.34 Mapk1ip1 Mitogen activated protein kinase 1 interacting protein 1 1.84 ± 0.22 Narf* Nuclear prelamin A recognition factor 2.12 ± 0.04 Plekha2 Pleckstrin homology domain-containing. family A. (phosphoinosite 2.15 ± 0.22 binding specific) member 2 Ptp4a2 Protein tyrosine phosphatase 4a2 - 2.04 ± 0.94 Rasa2* RAS p21 activator protein 2 - 2.80 ± 0.13 Rassf4 RAS association (RalGDS/AF-6) domain family 4 3.44 ± 2.56 Rgs18 Regulator of G-protein signaling - 1.93 ± 0.57 Rrad Ras-related associated with diabetes 1.81 ± 0.73 Sh3kbp1 SH3 domain kinase bindings protein 1 - 2.19 ± 0.53 Senp2 SUMO/sentrin specific protease 2 - 1.97 ± 0.49 Socs2 Suppressor of cytokine signaling 2 - 2.82 ± 0.85 Socs5 Suppressor of cytokine signaling 5 2.13 ± 0.08 Socs6 Suppressor of cytokine signaling 6 - 2.18 ± 0.38 Spry1 Sprouty 1 - 2.69 ± 0.19 Sos1 Son of sevenless homolog 1 (Drosophila) 2.16 ± 0.71 Ywhag 3-monooxygenase/tryptophan 5- monooxygenase activation protein. - 2.37 ± 1.42 gamma polypeptide Zfyve21 Zinc finger. FYVE domain containing 21 1.93 ± 0.57 Ligands and receptors Bambi BMP and activin membrane-bound inhibitor - 2.94 ± 0.62
    [Show full text]
  • FHL3 Contributes to EMT and Chemotherapy Resistance Through Inhibiting Ubiquitination of Slug and Activating Tgfβ/Smad-Independent Pathways in Gastric Cancer
    FHL3 Contributes to EMT and Chemotherapy Resistance Through Inhibiting Ubiquitination of Slug and Activating TGFβ/Smad-Independent Pathways in Gastric Cancer Guodong Cao First Aliated Hospital of Anhui Medical University Pengping Li Hangzhou Xiaoshan No 1 People's Hospital Qiang Sun Xuzhou Medical University Sihan Chen First Aliated Hospital of Anhui Medical University Xin Xu First Aliated Hospital of Anhui Medical University Xiaobo He First Aliated Hospital of Anhui Medical University Zhenyu Wang Hangzhou Xiaoshan No 1 People's Hospital Peng Chen First Aliated Hospital of Anhui Medical University Maoming Xiong ( [email protected] ) First Aliated Hospital of Anhui Medical University Bo Chen First Aliated Hospital of Anhui Medical University Research Keywords: EMT, Chemotherapy resistance, FHL3, Ubiquitination, Gastric cancer Posted Date: October 9th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-87249/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. ReLoaadd iFngu l[Ml LaitchJeanxs]/ejax/output/CommonHTML/jax.js Page 1/28 Loading [MathJax]/jax/output/CommonHTML/jax.js Page 2/28 Abstract Background: Gastric cancer presents high risk of metastasis and chemotherapy resistance. Hence, the mechanistic understanding of the tumor metastasis and chemotherapy resistance is quietly important. Methods: TCGA database and clinical samples are used for exploring the role of FHL3 in disease progression and prognosis. The roles of FHL3 in metastasis and chemotherapy resistance are explored in vitro and in vivo by siRNA or shRNA treatment. Finally, we explore the FHL3-mediated EMT and chemotherapy resistance. Results: mRNA and protein level of FHL3 is signicantly up-regulated in gastric cancer tissues when compares with it in adjacent tissue.
    [Show full text]
  • Architecture of a Lymphomyeloid Developmental Switch Controlled by PU.1, Notch and Gata3 Marissa Morales Del Real and Ellen V
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Caltech Authors DEVELOPMENT AND STEM CELLS RESEARCH ARTICLE 1207 Development 140, 1207-1219 (2013) doi:10.1242/dev.088559 © 2013. Published by The Company of Biologists Ltd Architecture of a lymphomyeloid developmental switch controlled by PU.1, Notch and Gata3 Marissa Morales Del Real and Ellen V. Rothenberg* SUMMARY Hematopoiesis is a classic system with which to study developmental potentials and to investigate gene regulatory networks that control choices among alternate lineages. T-cell progenitors seeding the thymus retain several lineage potentials. The transcription factor PU.1 is involved in the decision to become a T cell or a myeloid cell, and the developmental outcome of expressing PU.1 is dependent on exposure to Notch signaling. PU.1-expressing T-cell progenitors without Notch signaling often adopt a myeloid program, whereas those exposed to Notch signals remain in a T-lineage pathway. Here, we show that Notch signaling does not alter PU.1 transcriptional activity by degradation/alteration of PU.1 protein. Instead, Notch signaling protects against the downregulation of T-cell factors so that a T-cell transcriptional network is maintained. Using an early T-cell line, we describe two branches of this network. The first involves inhibition of E-proteins by PU.1 and the resulting inhibition of Notch signaling target genes. Effects of E- protein inhibition can be reversed by exposure to Notch signaling. The second network is dependent on the ability of PU.1 to inhibit important T-cell transcription factor genes such as Myb, Tcf7 and Gata3 in the absence of Notch signaling.
    [Show full text]
  • TRANSCRIPTIONAL REGULATION of Hur in RENAL STRESS
    TRANSCRIPTIONAL REGULATION OF HuR IN RENAL STRESS DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Sudha Suman Govindaraju Graduate Program in Biochemistry The Ohio State University 2014 Dissertation Committee: Dr. Beth S. Lee, Ph.D., Advisor Dr. Kathleen Boris-Lawrie, Ph.D. Dr. Sissy M. Jhiang, Ph.D. Dr. Arthur R. Strauch, Ph.D Abstract HuR is a ubiquitously expressed RNA-binding protein that affects the post- transcriptional life of thousands of cellular mRNAs by regulating transcript stability and translation. HuR can post-transcriptionally regulate gene expression and modulate cellular responses to stress, differentiation, proliferation, apoptosis, senescence, inflammation, and the immune response. It is an important mediator of survival during cellular stress, but when inappropriately expressed, can promote oncogenic transformation. Not surprisingly, the expression of HuR itself is tightly regulated at multiple transcriptional and post-transcriptional levels. Previous studies demonstrated the existence of two alternate HuR transcripts that differ in their 5’ untranslated regions and have markedly different translatabilities. These forms were also found to be reciprocally expressed following cellular stress in kidney proximal tubule cell lines, and the shorter, more readily translatable variant was shown to be regulated by Smad 1/5/8 pathway and bone morphogenetic protein-7 (BMP-7) signaling. In this study, the factors that promote transcription of the longer alternate form were identified. NF-κB was shown to be important for expression of the long HuR mRNA, as was a newly identified region with potential for binding the Sp/KLF families of transcription factors.
    [Show full text]
  • In Vivo Studies Using the Classical Mouse Diversity Panel
    The Mouse Diversity Panel Predicts Clinical Drug Toxicity Risk Where Classical Models Fail Alison Harrill, Ph.D The Hamner-UNC Institute for Drug Safety Sciences 0 The Importance of Predicting Clinical Adverse Drug Reactions (ADR) Figure: Cath O’Driscoll Nature Publishing 2004 Risk ID PGx Testing 1 People Respond Differently to Drugs Pharmacogenetic Markers Identified by Genome-Wide Association Drug Adverse Drug Risk Allele Reaction (ADR) Abacavir Hypersensitivity HLA-B*5701 Flucloxacillin Hepatotoxicity Allopurinol Cutaneous ADR HLA-B*5801 Carbamazepine Stevens-Johnson HLA-B*1502 Syndrome Augmentin Hepatotoxicity DRB1*1501 Ximelagatran Hepatotoxicity DRB1*0701 Ticlopidine Hepatotoxicity HLA-A*3303 Average preclinical populations and human hepatocytes lack the diversity to detect incidence of adverse events that occur only in 1/10,000 people. Current Rodent Models of Risk Assessment The Challenge “At a time of extraordinary scientific progress, methods have hardly changed in several decades ([FDA] 2004)… Toxicologists face a major challenge in the twenty-first century. They need to embrace the new “omics” techniques and ensure that they are using the most appropriate animals if their discipline is to become a more effective tool in drug development.” -Dr. Michael Festing Quantitative geneticist Toxicol Pathol. 2010;38(5):681-90 Rodent Models as a Strategy for Hazard Characterization and Pharmacogenetics Genetically defined rodent models may provide ability to: 1. Improve preclinical prediction of drugs that carry a human safety risk 2.
    [Show full text]
  • Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model
    Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 T + is online at: average * The Journal of Immunology , 34 of which you can access for free at: 2016; 197:1477-1488; Prepublished online 1 July from submission to initial decision 4 weeks from acceptance to publication 2016; doi: 10.4049/jimmunol.1600589 http://www.jimmunol.org/content/197/4/1477 Molecular Profile of Tumor-Specific CD8 Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A. Waugh, Sonia M. Leach, Brandon L. Moore, Tullia C. Bruno, Jonathan D. Buhrman and Jill E. Slansky J Immunol cites 95 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2016/07/01/jimmunol.160058 9.DCSupplemental This article http://www.jimmunol.org/content/197/4/1477.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 25, 2021. The Journal of Immunology Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A.
    [Show full text]
  • A Pathogenic Ctbp1 Missense Mutation Causes Altered Cofactor Binding and Transcriptional Activity
    neurogenetics (2019) 20:129–143 https://doi.org/10.1007/s10048-019-00578-1 ORIGINAL ARTICLE A pathogenic CtBP1 missense mutation causes altered cofactor binding and transcriptional activity David B. Beck1 & T. Subramanian2 & S. Vijayalingam2 & Uthayashankar R. Ezekiel3 & Sandra Donkervoort4 & Michele L. Yang5 & Holly A. Dubbs6 & Xilma R. Ortiz-Gonzalez7 & Shenela Lakhani8 & Devorah Segal9 & Margaret Au10 & John M. Graham Jr10 & Sumit Verma11 & Darrel Waggoner12 & Marwan Shinawi13 & Carsten G. Bönnemann4 & Wendy K. Chung14 & G. Chinnadurai2 Received: 23 October 2018 /Revised: 18 March 2019 /Accepted: 9 April 2019 /Published online: 30 April 2019 # Springer-Verlag GmbH Germany, part of Springer Nature 2019 Abstract We previously reported a pathogenic de novo p.R342W mutation in the transcriptional corepressor CTBP1 in four independent patients with neurodevelopmental disabilities [1]. Here, we report the clinical phenotypes of seven additional individuals with the same recurrent de novo CTBP1 mutation. Within this cohort, we identified consistent CtBP1-related phenotypes of intellectual disability, ataxia, hypotonia, and tooth enamel defects present in most patients. The R342W mutation in CtBP1 is located within a region implicated in a high affinity-binding cleft for CtBP-interacting proteins. Unbiased proteomic analysis demonstrated reduced interaction of several chromatin-modifying factors with the CtBP1 W342 mutant. Genome-wide transcriptome analysis in human glioblastoma cell lines expressing -CtBP1 R342 (wt) or W342 mutation revealed changes in the expression profiles of genes controlling multiple cellular processes. Patient-derived dermal fibroblasts were found to be more sensitive to apoptosis during acute glucose deprivation compared to controls. Glucose deprivation strongly activated the BH3-only pro-apoptotic gene NOXA, suggesting a link between enhanced cell death and NOXA expression in patient fibroblasts.
    [Show full text]
  • Supplementary Figure 1. Qrt-PCR Analyses for Measuring the Knockdown Efficiency of Transcription Factors. A549 and U937 Cells Kn
    Supplementary Figure 1. qRT-PCR analyses for measuring the knockdown efficiency of transcription factors. A549 and U937 cells knocking down or overexpressing different transcription factors including NF-κB subunits p65 and p50 (A), HIF1 (B), TCF4 (C), AP-1 subunits c-Jun and c-FOS (D), or FOXP3 (E) were subjected to RNA isolation, followed by qRT-PCR analyses to examine the expression of these transcription factors. **P<0.01 and ***P<0.001. 1 Supplementary Figure 2. Effects of FOXP3 downregulation and overexpression on the expression of NLRP1, IL1B and IL18. A549 and U937 cells were transfected with si-FOXP3 or pCDNA3-2×Flag-FOXP3. After 24 h, cells were subjected to RNA isolation, followed by qRT-PCR analyses to examine the expression of NLRP1 (A), IL1B (B) and IL18 (C). ***P<0.001. 2 Supplementary Figure 3. Effects of CtBP2 downregulation and overexpression on the expression of miR-199a-3p, NLRP1, IL1B and IL18. A549 and U937 cells were transfected with si-CtBP2 or pCDNA3-2×Flag-CtBP2. After 24 h, cells were subjected to RNA isolation, followed by qRT-PCR analyses to examine the expression of miR-199a-3p (A), NLRP1 (B), IL1B (C) and IL18 (D). ***P<0.001. 3 Supplementary Figure 4. CHFTC specifically bond to the promoter of miR-199a-3p. (A and B) Effects of CtBP2 knockdown and overexpression on HDAC1 and FOXP3 protein levels. A549 cells were transfected with two CtBP2-specific shRNAs and pCDNA3-2×Flag-CtBP2 to obtain two CtBP2-knockdown cell lines (KD-1 and KD-2) (A) and two CtBP2-overexpression cells lines (OE-1 and OE-2) (B), respectively.
    [Show full text]
  • Bioinformatic Analysis of Structure and Function of LIM Domains of Human Zyxin Family Proteins
    International Journal of Molecular Sciences Article Bioinformatic Analysis of Structure and Function of LIM Domains of Human Zyxin Family Proteins M. Quadir Siddiqui 1,† , Maulik D. Badmalia 1,† and Trushar R. Patel 1,2,3,* 1 Alberta RNA Research and Training Institute, Department of Chemistry and Biochemistry, University of Lethbridge, 4401 University Drive, Lethbridge, AB T1K 3M4, Canada; [email protected] (M.Q.S.); [email protected] (M.D.B.) 2 Department of Microbiology, Immunology and Infectious Disease, Cumming School of Medicine, University of Calgary, 3330 Hospital Drive, Calgary, AB T2N 4N1, Canada 3 Li Ka Shing Institute of Virology, University of Alberta, Edmonton, AB T6G 2E1, Canada * Correspondence: [email protected] † These authors contributed equally to the work. Abstract: Members of the human Zyxin family are LIM domain-containing proteins that perform critical cellular functions and are indispensable for cellular integrity. Despite their importance, not much is known about their structure, functions, interactions and dynamics. To provide insights into these, we used a set of in-silico tools and databases and analyzed their amino acid sequence, phylogeny, post-translational modifications, structure-dynamics, molecular interactions, and func- tions. Our analysis revealed that zyxin members are ohnologs. Presence of a conserved nuclear export signal composed of LxxLxL/LxxxLxL consensus sequence, as well as a possible nuclear localization signal, suggesting that Zyxin family members may have nuclear and cytoplasmic roles. The molecular modeling and structural analysis indicated that Zyxin family LIM domains share Citation: Siddiqui, M.Q.; Badmalia, similarities with transcriptional regulators and have positively charged electrostatic patches, which M.D.; Patel, T.R.
    [Show full text]
  • Supplementary Information Integrative Analyses of Splicing in the Aging Brain: Role in Susceptibility to Alzheimer’S Disease
    Supplementary Information Integrative analyses of splicing in the aging brain: role in susceptibility to Alzheimer’s Disease Contents 1. Supplementary Notes 1.1. Religious Orders Study and Memory and Aging Project 1.2. Mount Sinai Brain Bank Alzheimer’s Disease 1.3. CommonMind Consortium 1.4. Data Availability 2. Supplementary Tables 3. Supplementary Figures Note: Supplementary Tables are provided as separate Excel files. 1. Supplementary Notes 1.1. Religious Orders Study and Memory and Aging Project Gene expression data1. Gene expression data were generated using RNA- sequencing from Dorsolateral Prefrontal Cortex (DLPFC) of 540 individuals, at an average sequence depth of 90M reads. Detailed description of data generation and processing was previously described2 (Mostafavi, Gaiteri et al., under review). Samples were submitted to the Broad Institute’s Genomics Platform for transcriptome analysis following the dUTP protocol with Poly(A) selection developed by Levin and colleagues3. All samples were chosen to pass two initial quality filters: RNA integrity (RIN) score >5 and quantity threshold of 5 ug (and were selected from a larger set of 724 samples). Sequencing was performed on the Illumina HiSeq with 101bp paired-end reads and achieved coverage of 150M reads of the first 12 samples. These 12 samples will serve as a deep coverage reference and included 2 males and 2 females of nonimpaired, mild cognitive impaired, and Alzheimer's cases. The remaining samples were sequenced with target coverage of 50M reads; the mean coverage for the samples passing QC is 95 million reads (median 90 million reads). The libraries were constructed and pooled according to the RIN scores such that similar RIN scores would be pooled together.
    [Show full text]
  • Autism Multiplex Family with 16P11.2P12.2 Microduplication Syndrome in Monozygotic Twins and Distal 16P11.2 Deletion in Their Brother
    European Journal of Human Genetics (2012) 20, 540–546 & 2012 Macmillan Publishers Limited All rights reserved 1018-4813/12 www.nature.com/ejhg ARTICLE Autism multiplex family with 16p11.2p12.2 microduplication syndrome in monozygotic twins and distal 16p11.2 deletion in their brother Anne-Claude Tabet1,2,3,4, Marion Pilorge2,3,4, Richard Delorme5,6,Fre´de´rique Amsellem5,6, Jean-Marc Pinard7, Marion Leboyer6,8,9, Alain Verloes10, Brigitte Benzacken1,11,12 and Catalina Betancur*,2,3,4 The pericentromeric region of chromosome 16p is rich in segmental duplications that predispose to rearrangements through non-allelic homologous recombination. Several recurrent copy number variations have been described recently in chromosome 16p. 16p11.2 rearrangements (29.5–30.1 Mb) are associated with autism, intellectual disability (ID) and other neurodevelopmental disorders. Another recognizable but less common microdeletion syndrome in 16p11.2p12.2 (21.4 to 28.5–30.1 Mb) has been described in six individuals with ID, whereas apparently reciprocal duplications, studied by standard cytogenetic and fluorescence in situ hybridization techniques, have been reported in three patients with autism spectrum disorders. Here, we report a multiplex family with three boys affected with autism, including two monozygotic twins carrying a de novo 16p11.2p12.2 duplication of 8.95 Mb (21.28–30.23 Mb) characterized by single-nucleotide polymorphism array, encompassing both the 16p11.2 and 16p11.2p12.2 regions. The twins exhibited autism, severe ID, and dysmorphic features, including a triangular face, deep-set eyes, large and prominent nasal bridge, and tall, slender build. The eldest brother presented with autism, mild ID, early-onset obesity and normal craniofacial features, and carried a smaller, overlapping 16p11.2 microdeletion of 847 kb (28.40–29.25 Mb), inherited from his apparently healthy father.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]